AT
BCRX icon

Arlington Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

Arlington Trust’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5K Buy
+150
New +$1.36K ﹤0.01% 706

Other funds holding BCRX

WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $247M AUM 24.53% 1-Year Est. Return
CWS
Cypress Wealth Services Palm Desert, California $815M AUM 27.86% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Arlington Trust's BCRX Position: Q2 2026 in Review

Arlington Trust opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 150 shares worth $1.5K. The stake represents ﹤0.01% of the portfolio and ranks #706 among its holdings.

25 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Arlington Trust held 150 shares of BioCryst Pharmaceuticals worth $1.5K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Arlington Trust position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #706 holding.
  • 25 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.